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INTRODUCTION
Approximately, two billion people in the world have been 
infected by Hepatitis B virus (HBV), 350 million of  whom 
are chronic carriers of  the virus[1,2]. Worldwide HBV 
isolates have been classifi ed into eight genotypes: A, B, C, D, 
E, F, G and H[1,3]. The eight genotypes have a characteristic 
geographical distribution[1]. Several studies have revealed 
the association of  HBV genotypes with the severity of  
chronic liver disease, but the results are not consistent [1, 4-6]. 
In Europe, most patients with genotype D are reported to 
have acute hepatitis B, while most patients with genotype 
A have chronic hepatitis B[5]. In northern Taiwan, 52% 
of  asymptomatic carriers have genotype B, while 60% of  
patients with cirrhosis harbor genotype C; genotype B is 
more common in patients less than 50 years of  age with 
HCC[7]. In Japan, HCC patients with genotype B younger 
than 60 years of  age are rare[8]. Thus, the influences of  
HBV genotypes on clinical outcomes need to be clarifi ed. 
Recent studies have shown that virological characteristics 
and clinical manifestations may differ even among HBV 
isolates of  the same genotype[1]. Two subgroups of  
genotype B can be differentiated: a Japanese subgroup Bj 
with no indication for recombination events and an Asian 
subgroup called Ba which shows a recombination of  the 
precore and core region from HBV genotype C. Response 
to antiviral therapies and the prevalence of  hepatitis B e 
antigen (HBeAg) differ among patients with chronic liver 
diseases who are infected with HBV/Ba and HBV/Bj. 
Also, among isolates of  HBV genotype A (HBV/A), two 
subtypes have been reported, one of  which is distributed 
widely in European countries and the USA (Subtype A), 
while the other prevails in sub-Saharan Africa (Subtype 
A’). Subtype A’ seems to be virologically distinct from the 
original genotype A and is associated with reduced serum 
levels of  HBV DNA and a low capacity to encode HBeAg. 
In addition, subtype A’ tends to induce hepatocellular 
carcinoma[1]. HBV genotype C isolates from Australian 
Aboriginees shows several features of  a separate subgroup 
called genotype Caustralia. The South American genotype F 
segregates into two clades F1 and F2 [1]. 
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Abstract
AIM: To study the Hepatitis B virus (HBV) genotypes and 
their effect on the progression and outcome in patients 
with chronic liver diseases from New Delhi, India. 
METHODS: Sera from 100 HBV-related chronic liver 
disease (CLDB) cases were tested for HBV genotype 
using Polymerase Chain Reaction-Restriction Fragment 
Length Polymorphism (PCR-RFLP) and Type-specific 
primers-based PCR (TSP-PCR) targeting to the surface (S) 
gene encoding hepatitis B surface antigen. 
RESULTS: Only genotypes A and D were present and 
genotype D was dominant. Genotype D was present in 
all CLDB patient categories. The genotype distribution 
for the 100 patients with CLDB was as follows: genotype 
A, 16/100 (16%) (7/40- 17% chronic hepatitis B (CHB); 
8/47, 17%, HBV-related cirrhosis (CRB); 1/13, 7.6%, 
HBV-related hepatocellular carcinoma (HCCB); genotype 
D- 84/100 (84%) (32/40- 80% CHB; 38/47- 81%, CRB; 
11/13, 85%, HCCB); genotype A + D, 3/100 (3%) (1/40- 
3% CHB; 1/47- 2%, CRB; 1/13, 7.6%, HCCB); C, 0; B, 0; 
E, 0; F, 0; G 0, H 0; (P < 0.01, genotype D vs  A). 
CONCLUSION: Only HBV genotypes A and D were 
present in patients with CLDB from New Delhi, India. 
Compared with genotype D, genotype A patients had no 
signifi cant clinical or biochemical differences (P > 0.05). 
Mixed infection with genotype A and D were seen in 3% 
of the cases. Genotype D was the dominant genotype 
prevalent in all patient categories.
© 2006 The WJG Press. All rights reserved.
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Scanty information exists regarding the prevalence of  
HBV genotypes, their clinical relevance and therapeutic 
impact within CLDB category from India[9-12]. We have 
used recently developed two genotyping methods based 
on restriction fragment length polymorphism (RFLP)[13] 
and polymerase chain reaction (PCR) with type-specific 
primers[14] both targeting to the S-gene encoding the 
hepatitis B surface antigen. 
MATERIALS AND METHODS
Patients
The study subjects included HBV DNA positive patients 
belonging to different clinical categories: (1) The diagnosis 
of  HBV-related cirrhosis (CRB) was made when the 
patients presented with features of  HBV-related chronic 
liver disease associated with portal hypertension, had 
biochemical evidence of  hepatocellular failure and barium 
swallow or endoscopy showed evidence of  esophageal 
varices (When possible confirmation was done by 
histology). Other causes of  portal hypertension were 
excluded on the basis of  clinical features, liver function 
tests, and liver biopsy. The severity of  the cirrhosis was 
quantifi ed using the Childs-Pugh Classifi cation strategy[15]. 
Forty-seven CRB cases were selected on the basis of  
the above-mentioned criteria. (2) Patients with infection 
of  HBV showing symptomatic, biochemical (alanine 
aminotransferase more than upper limit of  normal) or 
serological (hepatitis B surface Antigen (HBsAg), Hepatitis 
B e Antigen (HBeAg), IgG antibodies to hepatitis B 
core antigen (IgG- Anti- HBc) positivity), evidence of  
continued liver disease of  more than 3 to 6 mo without 
steady improvement were diagnosed as suffering from 
Chronic Hepatitis B (CHB)[9-12,15]. Forty CHB cases were 
selected based on the above-mentioned criteria. (3) HBV 
related hepatocellular carcinoma (HCCB) was diagnosed in 
those HBV related cases when a percutaneous liver biopsy 
showed histological features of  a primary malignancy of  
hepatocytes and/or alfa-fetoprotein levels of  more than 30 
nanogm/mL[1,12,15]. Thirteen HCCB cases were selected on 
the basis of  the above-mentioned criteria. 
Sample size estimation 
With the assumption of  prevalence of  HBV, based on 
Indian Council of  Medical Research (ICMR), Government 
of  India, multicenter data[10-12], to be 70 % in chronic 
hepatitis (CH), 80% in liver cirrhosis (CRR), 60% in 
hepatocellular carcinoma (HCC), the minimum sample size 
required at 80% power level and 5% level of  signifi cance 
would be 30 cases each of  HBV-related liver cirrhosis 
(CRB) and chronic hepatitis B (CHB) and 11 HBV-
related hepatocellular carcinoma (HCCB). This sample 
size was achieved and some more cases were included by 
consecutive screening of  900 cases of  various chronic 
liver disease patients over a period of  42 mo (June 2002 
to December 2005). The study was approved by the 
institutional ethical committee of  Maulana Azad Medical 
College, New Delhi. Study protocol was explained to all 
eligible participants and informed consent was obtained 
before subject enrollment. 
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Serological tests
Serological status was investigated by the third generation 
enzyme immuno-assay (EIA) method using the following 
commercially available EIA kits: hepatitis B surface antigen 
(HBsAg), hepatitis B e antigen (HBeAg), IgG antibodies to 
hepatitis B core antigen (IgG- Anti- HBc), IgG antibodies 
to hepatitis D (IgG anti-HDV) (Abbott Laboratories, 
Chicago, IL, USA) and anti-HCV by Innotest HCV AB ? 
(Innogenetics NV, Ghent, Belgium). 
Biochemical investigations
Serum aspartate aminotransferase (AST), serum alanine 
aminotransferase (ALT), alkaline phosphatase (ALP), total 
bilirubin (T. Bil.), Prothrombin time (PT) tests were done 
weekly when the patients were admitted to the wards, while 
routine biochemical tests were done at monthly follow-up 
after the patients were discharged from the hospital. 
Lamivudine therapies for CHB patients
In all CHB cases, Lamivudine monotherapy was provided. 
The drug was given at a dose of  100 mg per day for 18 
mo. End of  therapy response (ETR) in HBeAg positive 
patients was defi ned as loss of  HBeAg (with or without 
the appearance of  anti-HBe), reduction of  viral DNA to 
undetectable level and normalization of  ALT. However, in 
HBeAg negative/anti-HBe positive patients it was defi ned 
as loss of  viral DNA accompanied with the normalization 
of  ALT[16]. Sustained virological response (SVR) was 
considered when the status of  ETR persisted for six 
months after the therapy was stopped [16].
DNA extraction and amplification of S-gene of HBV by 
PCR
Total nucleic acid from 100 μL serum was isolated using 
standard Proteinase-k/ phenol/ chloroform method[7]. Part 
of  the S-gene was amplifi ed by nested PCR as described 
earlier[13].
Determination of HBV genotypes by RFLP analysis of 
S-gene
The second round PCR Product with a length of  485 bp 
was subjected to digestion with five kinds of  restriction 
enzymes i.e. Ear ?, Alw ?, Nci ?, Hph ?, Nla ?[13]. 
Determination of HBV genotypes by PCR using type-
specifi c primers
Genotyping was done on the basis of  PCR based type-
specifi c DNA bands as performed earlier by Naito H et al 
2001[14].
Sensitivity of TSP-PCR
The amount of  DNA corresponding to 100 μL of  serum 
was dissolved in 25 μL of  sterile deionised water and 10 
μL was subjected to PCR. A 10-1 to 10-6 dilution of  this 
sample was used to determine the sensitivity of  the PCR 
protocol. Products were obtained up to 10-5 dilution. The 
detection limit of  the PCR was calculated to be 200 HBV 
genomes/mL serum. 
HBV Genotype analysis based on nucleotide sequencing
Representative PCR amplified products of  S-gene (485 
bases) were sequenced using the dideoxy chain termination 
method in an automated DNA sequencer (ABI 377-18 
sequencing system, Perkin Elmer). Nucleotide sequences 
were aligned with CLUSTALW software. DNA sequences 
of  Genotypes A-H were downloaded from the Gene bank 
according to the accession numbers for the respective 
genotype and phylogenetic analysis was carried out with 
the CLUSTALW algorithm.
Statistical analysis
Quantitative data was expressed as mean ± SD (Standard 
Deviation). Statistical signifi cance was determined by Chi-
square test with Yates’ correction (wherever needed) or by 
2-sided Fisher exact test and Student’s t test using SPSS-10 
software. The p values of  less than 0.05 were considered 
signifi cant throughout.
RESULTS
Demographic and clinical profi le of the patients
The S-gene of  HBV isolates from 100 various CLDB 
pat ients were ana lyzed for HBV genotypes. The 
demographic and baseline clinical characteristics of  the 
patients belonging to the three different groups (CHB, 
CRB, HCCB) is shown in Table 1. In all the three groups, 
the frequency of  male patients was more than the female 
patients (Table 1). None of  the patients was anti-HCV or 
anti-HDV positive as revealed by EIA tests.
HBV genotyping by PCR-RFLP
The PCR products of  100 HBV DNA positive subjects 
were digested with restriction enzymes specific for 
genotypes B, C, E and F and no characteristic fragment for 
each genotype was observed. Finally, by digestion with Nla 
IV, characteristic fragments of  genotype A were observed 
in 16 subjects, characteristic fragments of  genotype D 
were found in 81 subjects (Figure 1). Genotypes A+D 
mixed infections were found in three cases (Table 1).
HBV genotyping by PCR with type specifi c primers
As explained in the methodology two sets of  the 2nd PCR 
was carried out for detection of  genotypes A to F. Sixteen 
(16%) of  the 100 subjects had a PCR product of  68 bp 
that was characteristic of  genotype A (Figure 2). The other 
81/100 (81%) had PCR product a length of  119 bp and 
were classifi ed into genotype D. Genotype A + D mixed 
infections were found in three cases (Table 1).
Verifi cation of RFLP and TSP-PCR genotyping methods by 
sequencing
Twenty representative sequences were selected randomly 
from both genotype A (n = 5) and D (n = 15) samples. 
The 20 sequences were recorded in Gen Bank (Accession 
numbers: DQ875877 and DQ885267-DQ885285). A 
phylogenetic tree was constructed based on 410 bp of  the 
S-gene of  the HBV genome using CLUSTALW software. 
Out of  the 20 isolates, 15 isolates were clustered with 
Table 1  Demographic and clinical characteristics of patients in 
the three study groups
Parameters CRB CHB HCCB
n 47 40 13
Male: Female 41:6 36:4 11:2
(6.8:1) (9:1) (5.5:1) 
Mean age (yr)   38.36 ± 4.13a    37.65 ± 9.49    47.80 ± 18.70 
ALT (nKat/ L) 1333 ± 483       1200 ± 579.5    908.5 ± 363.4
AST (nKat/L) 1152 ± 620 1283.6 ± 483    971.4 ± 360
Total Bil. 
(μmol/ L)
  0.00016 ± 0.00012 0.00147 ± 0.00218 0.0028 ± 0.00032
IgG anti-HBc   91% 94% 93%
Risk factors
Transfusions   27% 27% 24%
Tattoo   7% 5%   6%
Operation   8% 4%   6%
Intravenous 
drug abuse
  5% 6%   3%
Unknown 53% 58% 61%
Genotype A      (8/47) 17%      (7/40) 17% (1/13) 7.6%
Genotype Db      (38/47) 81%      (32/40) 80% (11/13) 85% 
Genotype A+D      (1/47) 2%      (1/40) 3% (1/13) 7.6%
HBeAg +ve (%) 77%a 82%a 51%
Sustained 
virological 
response to 
therapy 
Genotype 
A:  (2/ 7) 28.5%
Genotype 
D: (12/32) 37.5%
(P = NS)       
aP < 0.05 vs HCCB; bP < 0.01 vs Genotype A; NS: Not signifi cant.
M        1        2        3        4        5        6        7
265 bp
265 bp
220 bp
186 bp
M        1       2       3       4       5      6       7        8
119 bp
 68 bp
Figure 1  Restriction Digestion of 485 bp PCR products into two fragments by 
Nla ?. M: Hae ??digested Phi ? 174 DNA ladder, Lanes 1- 4: Restriction 
Digestion of 485 bp into 265 bp and 186 bp fragments showing the presence of 
Genotype D; lanes 5,6: Restriction Digestion of 485 bp into 265 bp, 220 bp and 
186 bp fragments showing the presence of mixed Genotypes A and D; lanes 7: 
Restriction digestion of 485 bp into 265 bp and 220 bp fragments showing the 
presence of genotype A.
Figure 2  Agarose gel electrophoresis of HBV genotypes A and D, (Using Mix-A, 
Mix-B, PCR with type-specifi c primers based genotyping strategy). PCR Product 
of 119 base pairs (type D) and 68 base pairs (type A). Lane M- (Phi ? 174Hae 
?) Molecular weight marker, lane 1, 3- Negative Control, lane2-Positive Controls, 
lanes 4-8: Samples; Lanes 4, 5, 8: Type D; Lanes 6, 7: Type A.
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genotype D, and five were clustered with genotype A, 
validating both the genotyping strategies. The genotype 
A and D sequences were further classified into subtype 
A1 and Di by blast analysis. None of  the sequences was 
clustered with the sequences of  the genotypes B, C, E, F, 
G or H.
Virological response in CHB patients
Sustained virological response on treatment with 
lamivudine was seen in 28.5% of  patients of  genotype 
A while it was seen in 37.5% of  patients of  genotype D 
(P value is not signifi cant) (Table 1). The clinical data of  
CHB patients on therapy harboring either genotype A or 
genotype D did not differ signifi cantly.   
Comparison of clinical profi les between genotypes A and 
D in northern India
The majority of  the cases turned out to be genotype D; 
81/100 (81%), followed by genotype A; 16/100 (16%) 
using both the genotyping methods. Genotypes A + D 
mixed infections were found in three cases (Table 1). The 
ALT and AST levels, mean age, and HBeAg, IgG anti-
HBc positivity were compared between genotypes A and 
D within each of  the study groups and no significant 
differences were observed (Table 1). However, ALT, AST, 
HBeAg and IgG-anti-HBc positivity were significantly 
different between HCCB and CHB/ CRB cases (P < 0.05 
CHB, CRB vs HCCB, Table 1). 
DISCUSSION
There have been no studies from nor thern India 
comparing the clinical outcome of  CLDB patients 
infected with different HBV genotypes using the TSP-
PCR method. We have attempted to validate two most 
commonly used methods originally described by Naito 
et al and Mizokami et al[13,14]. Genotypes determined by 
both the methods were concordant in all the subjects. 
The present study demonstrates that HBV genotype 
D is highly prevalent. This result, however, differs from 
that of  two earlier studies on chronic liver diseases where 
genotype A and D were found to be prevalent in equal 
proportions[9,17]. The major reason of  the different results 
might be due to the differential demographic distribution 
of  the HBV-genotypes. The previous study was carried 
out in Lucknow; a city situated 600 km away from New 
Delhi, India. Also, the majority of  the cases in Lucknow 
come from semi-urban and rural areas. The patients in 
New Delhi are more or less from urban or semi-urban 
areas[17]. Another reason could be selection bias, as earlier 
studies were conducted on small series of  non-consecutive 
chronic cases [9,17]. 
In this study, mixed infection of  genotypes A and D 
of  HBV were found in 2% CRB cases, 3% CHB and 7.6% 
HCCB cases. This is in accordance with what has been 
reported earlier[17]. Interestingly, all the cases (3/3) with 
mixed infections with genotype A and D had histories of  
blood transfusions. In our study, genotype A was found 
only in the minority of  the patient categories (Table 1). 
The impact of  HBV genotypes on response to lamivudine 
therapy has been studied in various countries[18]. A study 
in Germany suggested that the rate of  resistance to 
lamivudine was higher in patients with HBV genotype 
A infection than in patients with genotype D infection. 
No difference in the risk of  lamivudine resistance is 
found between patients with genotype B and patients 
with genotype C. In patients with genotype C infection, 
however, virological response is worse during lamivudine 
therapy, and is also less durable after the discontinuation 
of  therapy than in patients with genotype B infection[18]. 
The response to lamivudine is poorer in patients infected 
with subtype Ba, which contains a recombination with 
genotype C, than in those with subtype Bj without such a 
recombination[19]. Influence of  genotypes on therapeutic 
response needs to be examined in patients infected with 
the other genotypes, particularly in those with genotype 
A or D infection[19]. In the present study, a significantly 
higher percentage of  patients with CLDB were infected 
with genotype D and they did not infl uence the therapeutic 
response. Sustained virological response on treatment with 
lamivudine was seen in 28.5% of  patients of  genotype 
A while it was seen in 37.5% of  patients of  genotype D 
(P value is not significant). Determining the genotype 
could be helpful for predicting the outcome of  antiviral 
therapy in patients with chronic hepatitis B. Transfusion 
was associated as the most important risk factor of  HBV 
transmission in all the patient categories (Table 1).
Twenty representat ive samples from the study 
population were sequenced for the S-gene which led to 
confirmation of  the RFLP and TSP-PCR results. Based 
on the nucleotide sequence of  the S-region, genotype 
D emerged as the predominant genotype (15/20, 75%). 
Indian strains belonging to genotype A and D differed 
from each other by about 5.2% in the S-gene (410 bases). 
In conclusion, genotype D appears to be the dominant 
genotype circulating in north Indian population with 
CLDB. Genotype A appears to be the minor genotype. 
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